Dr. Tagawa Discusses the Development of Immunotherapy in Urothelial Cancer

Scott T. Tagawa, MD, MS
Published: Friday, Apr 14, 2017



Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.

Platinum-based chemotherapy has been a successful treatment for patients with urothelial cancer, but immunotherapies—particularly PD-1/PD-L1 antibodies—have captured much of the recent attention in the field, states Tagawa.

One-quarter of patients with urothelial cancer see durable responses with immunotherapy. Now, trials are focused on combination regimens, explains Tagawa.
 


Scott T. Tagawa, MD, MS, assistant professor of Medicine, medical director, Genitourinary Oncology Research Program, assistant attending physician, New York-Presbyterian Hospital, discusses the development of immunotherapy for patients with urothelial cancer.

Platinum-based chemotherapy has been a successful treatment for patients with urothelial cancer, but immunotherapies—particularly PD-1/PD-L1 antibodies—have captured much of the recent attention in the field, states Tagawa.

One-quarter of patients with urothelial cancer see durable responses with immunotherapy. Now, trials are focused on combination regimens, explains Tagawa.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x